Caplin Point Laboratories (524742) Q4 24/25 earnings summary

Executive summary

• Achieved consolidated revenue of INR 2,034 crore (₹2,034 Cr) for FY25, up 15.5% year-over-year, with PAT at INR 541 crore (₹541 Cr), up 17.3% year-over-year.

• US market EBITDA grew 71% YoY to over INR 102 crore, with strong growth in both Emerging and Regulated markets.

• Free cash reserves reached INR 1,180 crore, with liquid assets at INR 2,150 crore as of March 31, 2025.

• Expansion in Latin America, U.S., and new product launches, including insulin, peptide injectables, and oncology, are key growth drivers.

• Maintained a debt-free, cash-rich balance sheet, supporting ongoing capex and R&D investments from internal accruals.

Financial highlights

• Q4 FY25 revenue from operations: ₹502.5 Cr (up 10.9% YoY); FY25 revenue: ₹1,937.5 Cr (up 14.4% YoY).

• FY25 EBITDA: ₹743.4 Cr (up 20.2% YoY); EBITDA margin at 36.5%.

• Gross margin for FY25 reached 60.2%, with PAT margin at 26.6%.

• Free cash flow for FY25 at ₹240 Cr; cash and cash equivalents at ₹1,180 Cr.

• Basic EPS for FY25: ₹70.57 (up 17.2% YoY).

Outlook and guidance

• Expects 10-12 ANDA approvals in FY26, supporting further US market growth.

• Ongoing capex projects (~₹1,000 Cr) to expand production, product range, and backward integration, funded by internal accruals.

• Focus on asset-light outsourcing, backward integration, and expanding product registrations in regulated and emerging markets.

• Management expects a transitionary period of 18-24 months before significant growth from new initiatives materializes.

• $100 million revenue target for Caplin Steriles remains, though timing may extend by 12-18 months.